CureVac’s Vaccine Just 48% Effective Against COVID-19, Final Phase 3 Trial Results Show

The New York Times (6/30, Zimmer) reports CureVac on Wednesday issued “the final results of its late-stage vaccine trial, confirming earlier data showing that its” COVID-19 vaccine candidate “is far less protective than other vaccines,” reaching “an effic...